Brought to you by

Merck to develop Neuromed's pain compound; ended
11 Jun 2009
Executive Summary
Neuromed (drugs to treat chronic pain) has licensed Merck & Co. exclusive worldwide development and commercialization rights to its lead pain candidate NMED160, an N-type calcium channel blocker that is in Phase II clinical trials. Merck also gets rights to develop and sell compounds for other neurological indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com